Searching…
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics ...
Importantly, inhibition of MASP-2 preserves the classical and alternative complement functions, critical for defense against infection. Omeros is pursuing approval in Europe for narsoplimab to treat TA-TMA. To learn m...
3 days ago · Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.
Omeros Corp是一家生物制药公司。 该公司专注于发现、开发和商业化针对免疫疾病的大市场和孤儿适应症的小分子和蛋白质疗法，包括补体介导的疾病和与免疫系统功能障碍相关的癌症，以及成瘾和强迫症。
Omeros has a diverse pipeline of therapeutics, including PPARγ agonists (OMS405), PDE10 inhibitors (OMS824), MASP-2 Inhibitors (Narsoplimab), and many others.
At Omeros, we see strength in diversity. Our broad scientific expertise allows us to pursue indications across a spectrum of disease, addressing critical unmet needs.
Grow with Omeros – a team of exceptionally talented, passionate, collaborative, and diverse people. Learn more about open positions, benefits, and more.
Omeros is advancing novel research and development programs for small-molecule and protein therapeutics to address both orphan and large-market indications. Our current areas of focus include complement-mediated disea...
Feb 7, 2013 · Omeros Corporation - Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting The Investor Relations website contains information about Omeros Corporation's business for stockholders, po...
Learn the proprietary technologies Omeros has developed to discover antibodies and de-orphanize G protein-coupled receptors (GPCRs)
